Related Experiment Video
Updated: Jun 19, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Biochemical profiling to predict disease severity in metachromatic leukodystrophy
M A F Tan1, M Fuller, Z A M H Zabidi-Hussin
1Lysosomal Diseases Research Unit, SA Pathology at Women's and Children's Hospital, North Adelaide, SA 5006, Australia.
Molecular Genetics and Metabolism
|October 10, 2009
Summary
Metachromatic leukodystrophy (MLD) is a neurodegenerative disease diagnosed by measuring arylsulfatase A enzyme activity. Biochemical profiling can predict MLD phenotypes and progression rates in newborns, enabling timely treatment.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Metachromatic leukodystrophy (MLD) is a fatal neurodegenerative lysosomal storage disease caused by arylsulfatase A (ARSA) deficiency.
- Accumulation of sulfatides in the nervous system leads to severe neurological impairment and poor prognosis without early intervention.
- Pre-symptomatic diagnosis through newborn screening is crucial for effective treatment before clinical symptoms manifest.
Purpose of the Study:
- To develop predictive methods for clinical phenotype and disease progression in asymptomatic MLD individuals.
- To evaluate biochemical profiling for differentiating MLD subtypes and guiding treatment strategies.
- To assess the utility of residual ARSA enzyme activity and metabolite profiling for MLD diagnosis and prognosis.
Main Methods:
- Biochemical profiling of urine and cultured skin fibroblasts from MLD patients and controls.
- Immune-based assays to determine residual arylsulfatase A (ARSA) protein and activity.
- Electrospray ionization-tandem mass spectrometry for metabolite profiling, focusing on sulfatides and other lipids.
Main Results:
- Residual ARSA protein/activity effectively distinguished between unaffected individuals, pseudo-deficient variants, and affected MLD patients.
- Quantification of sulfatides and other lipids in urine and fibroblasts differentiated MLD phenotypes, including late-infantile, juvenile, and adult forms.
- Combined analysis of genotype, ARSA status, and lipid profiles predicted disease progression rates.
Conclusions:
- Biochemical profiling, including ARSA activity and lipid metabolite analysis, is essential for accurate MLD diagnosis and phenotype prediction.
- These methods enable differentiation of MLD subtypes and prediction of disease progression, crucial for personalized treatment selection.
- Integrating genotype, enzyme activity, and metabolite data offers a comprehensive approach to managing MLD, especially in pre-symptomatic individuals.
